Science News

NEW YORK--(BUSINESS WIRE)--VB Spine has received FDA Breakthrough Device Designation for a new blood test designed to identify patients at risk for scoliosis progression....

LONDON--(BUSINESS WIRE)--Keyron, developer of the ForePass® fully reversible metabolic bypass platform for severe metabolic disease, today announced that David Feigal, MD, was appointed Board Chair effective September 21, 2026. Dr Feigal will continue to lead Keyron’s regulatory strategy alongside his new role as Board Chair. He is the former Director of the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH), which regulates medical devices in the United State...

SAN FRANCISCO & SEOUL, South Korea--(BUSINESS WIRE)--Amorepacific and Junevity Partner to Develop Next-Generation Products for Skin Rejuvenation...

BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium...

BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a clinical-stage biotech company developing first-in-class small molecules derived from life's chemistry, today announced that new mechanistic and biomarker data from the Phase 1b trial of ENV-294 in moderate-to-severe atopic dermatitis were accepted for a late-breaking oral presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2026, to be held in Vienna, Austria from September 30 to October 3, 2026. “Being selected...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the initiation of THRIVE-2, a Phase 2 clinical study evaluating STM-01 in patients with Duchenne muscular dystrophy (DMD). The study is now open for enrollment, with the first patient expected to enroll imminently. THRIVE-2 is a multicenter, multi-dose, open-label Phase 2 study designed to evaluate the saf...

SAN DIEGO--(BUSINESS WIRE)--CytoHub Inc., a biotechnology company utilizing the CardioVive AI-integrated human heart assembloid platform for drug safety and efficacy prediction, today announced that Scientific Co-Founder Aitor Aguirre, PhD, has been appointed to key leadership roles at the National Institutes of Health’s newly established Standardized Organoid Modeling (SOM) Center in Frederick, Maryland. Dr. Aguirre will serve as Director of the Tissue Engineering Laboratories at the Frederick...

TAIPEI CITY, Taiwan--(BUSINESS WIRE)--Oneness Biotech completed the SAD portion of its Phase 1 trial evaluating SNS851 as a potential treatment for obesity-associated metabolic diseases....

NEW YORK--(BUSINESS WIRE)--Ortet, a frontier artificial intelligence lab for health, today announced its launch with a $500 million commitment from Thoreau, which is building the foundational compute, rules, and research infrastructure platform for health. Ortet will bring together compute and data infrastructure, frontier research, and model development and deployment to address health holistically across its biological, clinical, operational, and financial dimensions. Most healthcare AI tools...

TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital....